Validated anxiety assessments among pediatric patients with peanut allergy on oral immunotherapy

被引:2
|
作者
Kaman, Kelsey [1 ,4 ]
Dhodapkar, Meera [2 ]
Shabanova, Veronika [2 ]
McCollum, Sarah [2 ]
Factor, Jeffrey [1 ,3 ]
Leeds, Stephanie [2 ]
机构
[1] Connecticut Asthma & Allergy Ctr, Hartford, CT USA
[2] Yale Sch Med, New Haven, CT USA
[3] New England Food Allergy Treatment Ctr, Hartford, CT USA
[4] Connecticut Asthma & Allergy Ctr, 836 Farmington Ave 207, Hartford, CT 06119 USA
关键词
QUALITY-OF-LIFE; FOOD ALLERGY; DISPARITIES; MANAGEMENT; SYMPTOMS; CHILDREN; STRESS; IMPACT;
D O I
10.1016/j.anai.2023.01.028
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Although efficacy, safety, and quality of life measures associated with peanut oral immunotherapy (OIT) have been studied, the relationship between peanut OIT and clinical anxiety has not yet been evaluated. The latter is important to help providers and families have an improved shared medical decision discussion around the benefits of initiating OIT.Objective: To investigate the relationship between undergoing OIT and anxiety in patients with peanut allergy.Methods: In this prospective cross-sectional cohort study, using validated and age-appropriate anxiety scales administered with electronic survey questionnaires, we used generalized linear regressions to compare anxiety between patients undergoing OIT and similar patients with peanut allergy but not on OIT (controls).Results: In the younger cohort (<7 years, n = 80), there was generally a low prevalence of diagnosable anxiety across patients on OIT and controls. In the older cohort (>7 years, n = 125), there was a higher prevalence of anx-iety but no clinically meaningful difference between anxiety scores of patients on OIT and controls. In the older cohort, patients with asthma were more likely to have higher mean anxiety scores (P = .04), as were female patients compared with male patients (P = .004). A subanalysis of separation anxiety scores in the older cohort revealed that younger age (7-12 years vs >12 years, P < .001), non-White race (P = .04), and eczema (P = .02) were found to be meaningful predictors of higher scores. A subanalysis of social anxiety on the older cohort pointed toward non-White race as a meaningful predictor of higher scores (P < .02).Conclusion: The clinical implications of these findings suggest that allergists should particularly consider screen-ing children with food allergy for anxiety and anxiety subtypes among patients who are non-White, female, or have asthma.& COPY; 2023 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 663
页数:7
相关论文
共 50 条
  • [31] AR101 Oral Immunotherapy for Peanut Allergy
    Vickery, Brian P.
    Vereda, Andrea
    Casale, Thomas B.
    Beyer, Kirsten
    du Toit, George
    Hourihane, Jonathan O.
    Jones, Stacie M.
    Shreffler, Wayne G.
    Marcantonio, Annette
    Zawadzki, Rezi
    Sher, Lawrence
    Carr, Warner W.
    Fineman, Stanley
    Greos, Leon
    Rachid, Rima
    Ibanez, M. Dolores
    Tilles, Stephen
    Assa'ad, Amal H.
    Nilsson, Caroline
    Rupp, Ned
    Welch, Michael J.
    Sussman, Gordon
    Chinthrajah, Sharon
    Blumchen, Katharina
    Sher, Ellen
    Spergel, Jonathan M.
    Leickly, Frederick E.
    Zielen, Stefan
    Wang, Julie
    Sanders, Georgiana M.
    Wood, Robert A.
    Cheema, Amarjit
    Bindslev-Jensen, Carsten
    Leonard, Stephanie
    Kachru, Rita
    Johnston, Douglas T.
    Hampel, Frank C., Jr.
    Kim, Edwin H.
    Anagnostou, Aikaterini
    Pongracic, Jacqueline A.
    Ben-Shoshan, Moshe
    Sharma, Hemant P.
    Stillerman, Allan
    Windom, Hugh H.
    Yang, William H.
    Muraro, Antonella
    Zubeldia, Jose M.
    Sharma, Vibha
    Dorsey, Morna J.
    Chong, Hey J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21): : 1991 - 2001
  • [32] Oral and subcutaneous immunotherapy in a peanut allergy mouse model
    Wagenaar, L.
    Vonk, M. M.
    van Roest, M.
    Kruijssen, L. J. W.
    Knippels, L. M. J.
    van Esch, B. C. A. M.
    Pieters, R. H. H.
    Smit, J. J.
    ALLERGY, 2015, 70 : 200 - 200
  • [33] STOPping peanut allergy: the saga of food oral immunotherapy
    Greenhawt, Matthew J.
    LANCET, 2014, 383 (9925): : 1272 - 1274
  • [34] Peanut Allergy: first oral Immunotherapy is approved in Germany
    Ayazpoor, Ute
    ALLERGO JOURNAL, 2022, 31 (02) : 72 - 72
  • [35] Peanut Allergy: Preparation for oral Immunotherapy now approved
    Wepner, Ulrike
    ALLERGO JOURNAL, 2021, 30 (01) : 67 - 67
  • [36] Clinical Predictors of Successful Oral Immunotherapy in Peanut Allergy
    Olayiwola, Oluwatobi
    Mudd, Lauren
    Dunaway, Lars
    Sanda, Srinath
    Fulkerson, Patricia
    Huffaker, Michelle
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB446 - AB446
  • [37] Oral immunotherapy for peanut allergy in clinical practice is ready
    Mansfield, Lyndon E.
    ALLERGY AND ASTHMA PROCEEDINGS, 2013, 34 (03) : 205 - 209
  • [38] Oral Immunotherapy for Management of Peanut Allergy in Spanish Children
    Vila, L.
    Amado, A.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2016, 26 (03) : 207 - 209
  • [39] Oral Immunotherapy in Japanese Children with Anaphylactic Peanut Allergy
    Nagakura, Ken-ichi
    Sato, Sakura
    Yanagida, Noriyuki
    Nishino, Makoto
    Asaumi, Tomoyuki
    Ogura, Kiyotake
    Ebisawa, Motohiro
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2018, 175 (03) : 181 - 188
  • [40] Allergen-specific oral immunotherapy for peanut allergy
    Nurmatov, Ulugbek
    Venderbosch, Iris
    Devereux, Graham
    Simons, F. Estelle R.
    Sheikh, Aziz
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (09):